Drug updated on 4/17/2024
| Dosage Form | Injection (intravenous; 1 mg per 2 mL [0.5 mg per mL]) |
| Drug Class | Microtubule inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
- Indicated for the treatment of unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
Summary
- Eribulin mesylate (Halaven) is recommended for treating metastatic breast cancer and unresectable or metastatic liposarcoma, especially in those who have received at least two previous chemotherapy regimens. It has demonstrated a significant increase in overall survival compared to non-eribulin treatments in both main and sensitivity analyses.
- The analysis of Halaven's safety and effectiveness was conducted through three systematic reviews/meta-analyses, comparing it with other chemotherapy agents.
- Regarding progression-free survival, eribulin exhibited some limitations as it showed a statistically shorter duration compared to combinations such as capecitabine and ixabepilone, or capecitabine and utidelone.
- A notable adverse event associated with eribulin therapy is all-grade neutropenia, marking an area of concern for the drug's tolerability. Nonetheless, this toxicity profile is described as manageable.
- For triple-negative breast cancer (TNBC), a subtype often challenging to manage, eribulin resulted in longer overall survival than capecitabine, signifying potential advantages for this particular patient group.
- Review of real-world evidence suggests that the benefits seen in clinical trials are applicable to broader patient populations, including those with locally advanced breast cancer/metastatic disease, thereby supporting its general use beyond controlled environments.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Halaven (eribulin mesylate) Prescribing Information. | 2022 | Eisai Inc., Nutley, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis. | 2021 | Clinical Reviews in Oncology/Hematology |
| Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer. | 2021 | BioMed Central Cancer |
| Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer. | 2020 | Current Medical Research and Opinion |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Systemic anti-cancer therapy delivery in the home: a service model. | 2020 | British Journal of Nursing |